CVS HEALTH CORPORATION Cash and Cash Equivalents, Fair Value Disclosure
CVS HEALTH CORPORATION (CVS) had Cash and Cash Equivalents, Fair Value Disclosure of $11.33 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $11.33B.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $9.54B.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $8.45B.
- 2024-12-31: Cash and Cash Equivalents, Fair Value Disclosure $8.59B.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $11.33B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $9.54B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $8.45B 10-Q · filed 2026-08-05 |
| 2024-12-31 | $8.59B 10-K · filed 2026-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PETMED EXPRESS INC (PETS) | United States | $0.034B | -1.41 |